Monthly Archives: October 2015

Amlexanox, Obesity and the IKK-e and TBK1 Signalling Pathway

Previous posts have described some of the novel strategies and innovative technologies used to identify candidate biomarkers and therapeutic targets. But what comes next? How can researchers verify that putative biomarkers are biologically relevant and worthy of further research? Shannon Reilly et al.,1 deconstruct the signalling pathway that mediates obesity-induced inflammation, and elegantly demonstrate that […]

By |October 20th, 2015|Obesity|0 Comments

Plasma 1-Deoxysphingolipid Predicts Type 2 Diabetes in At-Risk Population

A research team led by Alaa Othman1 explored the “lipidome” to identify novel risk factors or biomarkers that predict the incidence of type 2 diabetes. The researchers measured sphingoid base profiles in a prospective cohort of 339 individuals who had already experienced a coronary event. The team determined whether this data could help predict which […]

By |October 14th, 2015|Diabetes|0 Comments

Anti-inflammatory Drugs Might Someday Treat Obesity

Obesity leads to chronic, low-grade local inflammation in the liver and adipose tissue. This local inflammation eventually results in insulin resistance and the development of type 2 diabetes. American researcher Jonathan Mowers and his team1 explored the complex molecular pathways linking obesity, inflammation and diabetes. Their investigation identified two potential therapeutic targets.

Previously, these researchers observed […]

By |October 7th, 2015|Diabetes, Obesity|0 Comments